We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
Read MoreHide Full Article
Sangamo Therapeutics, Inc. (SGMO - Free Report) was a big mover last session, as the company saw its shares rise nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.60 to $14.50 in the past one-month time frame.
The move came after the company reported that its Hunter syndrome treatment witnessed a new mileage when the first patient had been dosed in a phase 1/2 trial to evaluate the potential for its gene-editing technology.
Though the company has seen one positive estimate revision over the past few weeks, the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Sangamo Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Is SGMO going up? Or down? Predict to see what others think: Up or Down
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
Sangamo Therapeutics, Inc. (SGMO - Free Report) was a big mover last session, as the company saw its shares rise nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.60 to $14.50 in the past one-month time frame.
The move came after the company reported that its Hunter syndrome treatment witnessed a new mileage when the first patient had been dosed in a phase 1/2 trial to evaluate the potential for its gene-editing technology.
Though the company has seen one positive estimate revision over the past few weeks, the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Sangamo Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Sangamo Therapeutics, Inc. Price
Sangamo Therapeutics, Inc. Price | Sangamo Therapeutics, Inc. Quote
Another stock worth considering in the Medical - Biomedical and Genetics industry is Myriad Genetics, Inc. (MYGN - Free Report) which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Is SGMO going up? Or down? Predict to see what others think: Up or Down
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>